Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of IDO/Survivin Peptide Vaccine, GM-CSF, Imiquimod and Temozolomide Chemotherapy for Patients With Metastatic Malignant Melanoma

NCT01543464 is registered in ClinicalTrials.gov with Inge Marie Svane as lead sponsor.

NCT NCT01543464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01543464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of IDO/Survivin Peptide Vaccine, GM-CSF, Imiquimod and Temozolomide Chemotherapy for Patients With Metastatic Malignant Melanoma
Lead sponsor
Inge Marie Svane
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2012
Completion date
September 30, 2016
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma